In summary, our results suggest that targeting p/CIP and SRC-1 may not only reduce obesity but also enhance glucose uptake and insulin sensitivity, which would offer benefits not obtained by using TZDs for treatment of diabetes. This evidence concerns the gene INS and diabetes mellitus.